Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
- Tanabe to Continue Strategic Technical Alliances with Foreign Companies
December 24, 2001
- Sysmex Develops Hemocytometer for POC Use
December 24, 2001
- 33 JPMA Member Companies: Sales Up 2.4%, Profits Up 56.5%
December 24, 2001
- Pharmacia to Spin Off Stake in Monsanto
December 24, 2001
- WORLD NEWS I N BRIEF
December 17, 2001
- Basic Policy for FY2002 Budget Approved
December 17, 2001
- 1st Large Epidemiologic Study on Arteriosclerotic Disease to Start in Japan
December 17, 2001
- Medical Fees to Be Reduced: The Question Is How Much
December 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 17, 2001
- Domestic Drug Production Down 1.7% to \6,18 Trillion in FY2000
December 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 17, 2001
- 17th Quality Reevaluation to Start on 18 Mono-drugs, 8 Combinations
December 17, 2001
- Sephora to Withdraw from Japan
December 17, 2001
- Quality Reevaluation Completed for Drugs Accounting for 60% of Total Market
December 17, 2001
- Matsumotokiyoshi: Sales, Net Profits Increase 11%, 46.1%, Respectively
December 17, 2001
- REGULATORY NEWS IN BRIEF
December 17, 2001
- Kraft: Dispensing Business Boosts Sales by 16.8%
December 17, 2001
- FTC Issues Recommendation to 9 Wholesalers in the Tohoku Region
December 17, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…